Related Experiment Videos
[Clinical effects of ceftizoxime suppositories in pediatric infections]
Insights
Ceftizoxime suppositories (CZX-S) demonstrated 100% effectiveness in treating pediatric infections like pneumonia and UTI. This study found no adverse effects, making CZX-S a safe and effective option for children undergoing chemotherapy.
Area of Science:
- Pediatric Oncology
- Infectious Diseases
- Pharmacology
Background:
- Chemotherapy in pediatric patients can increase infection risk.
- Ceftizoxime suppositories (CZX-S) offer an alternative dosage form for pediatric infections.
- Physician discretion guides the use of CZX-S when this form is deemed optimal.
Observation:
- A clinical trial involved 5 pediatric patients with infections (pneumonia, tonsillitis, UTI).
- CZX-S was administered to children whose chemotherapy regimen was best suited for this dosage form.
- The study monitored clinical response, adverse events, laboratory tests, and drug concentrations.
Findings:
- CZX-S achieved a 100% effectiveness rate, with 3 patients showing marked effectiveness and 2 showing effectiveness.
- No adverse drug reactions or abnormal laboratory findings were observed.
- No instances of suppository expulsion occurred, ensuring consistent drug delivery.
- Pharmacokinetic data showed therapeutic serum concentrations (8.38-11.4 µg/ml) and high urinary concentrations (23.6-290 µg/ml) of ceftizoxime.
Implications:
- CZX-S presents a safe and highly effective treatment option for pediatric infections, particularly in immunocompromised children.
- The favorable safety profile and pharmacokinetic results support the use of CZX-S in pediatric oncology settings.
- This study highlights the potential of suppository formulations for targeted drug delivery in specific pediatric patient populations.
Abstract:
A clinical trial of ceftizoxime suppositories (CZX-S) was conducted in children whose chemotherapy was considered to be best performed in this dosage form at the physician's discretion. The subjects were 5 children with infection, consisting of 2 with pneumonia, 1 with tonsillitis, and 2 with UTI. The results were as follows. The clinical response to CZX-S was "markedly effective" in 3 and "effective" in 2, with the 100% effectiveness rate. Neither adverse drug reactions nor abnormal laboratory tests were detected. No unwanted expulsion of the suppository occurred. The serum concentration of CZX 30 minutes after the first insertion ranged from 8.38 to 11.4 micrograms/ml, and the urinary concentration of CZX in the 6-hour urine collections, from 23.6 to 290 micrograms/ml.